Category Archives: Global News Feed

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023

Here is the original post:
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.

Read the rest here:
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.

See the rest here:
VYNE Therapeutics Reports Second Quarter 2022 Financial Results

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.

Original post:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022

More:
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release

View post:
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval

Read more:
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine...

SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.

View original post here:
Clene to Host VISIONARY-MS Results Call and Webcast on August 15

Conference call begins at 11:00 a.m. Eastern time today

Read the original:
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update

REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.

Originally posted here:
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update